IMARA (IMRA) EHA Investor Presentations - Slideshow

Advancing Novel Treatments for Hemoglobin Disorders Investor Call: June 11, 2021 CONFIDENTIAL Forward-Looking Statements and Disclaimer 2 This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, (i) the clinical trial design and timing with respect to reporting of data from the Ardent and Forte Phase 2b clinical trials in patients with sickle cell disease and beta-thalassemia, (ii) t ...